English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The aim of the study was to evaluate the effect of the drug therapy assigned at the index visit on the risk of fatal outcome in outpatients with coronary heart disease within 24 months from the index visit, based on the data of registry of cardiovascular diseases (RECVASA). Follow-up feedback was 97.4%, the survival rate - 90.6%. The study found that the prescribing of angiotensin-converting enzyme (ACE) inhibitors or ACE inhibitors/angiotensin receptor blockers II (ARB) was associated with reduction of all-cause mortality by 1.6 times (p=0.016) and 2.0 times (p=0.006), respectively, statins - by 1.6 times (p=0.038). The risk of death from cardiovascular causes in the case of prescribing of ACE inhibitors or ACE inhibitors/ARBs decreased by 2.1 times (p=0.0008) and 2.3 times (p=0.0008), respectively, statins - by 1,7 times (p=0.048).

cardiosomatika

Impact of drug therapy on the risk of death in patients with coronary heart disease (according to the data of registry of cardiovascular diseases, RECVASA)